TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06152276

Intervention type: OTHER
Intervention: Diverting loop ileostomy
Description: Diverting loop ileostomy following low anterior resection of colorectal cancer
Study: NCT05456035

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy plus social cognitive training (CBTSCT)
Description: The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy plus social cognitive training (CBTSCT)
Description: The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
Study: NCT06487039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-203
Description: Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-203
Description: Subjects will receive EB-203 according to the following dosage and administration method for each treatment group.
Study: NCT06573203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-contact heart rate and respiratory rate monitoring system
Description: Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-contact heart rate and respiratory rate monitoring system
Description: Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-contact heart rate and respiratory rate monitoring system
Description: Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindray ECG monitor
Description: Heart rate and respiratory rate of each enrolled child were monitored after admission.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aEEG
Description: Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.
Description: The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
Study: NCT05715645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral prosthetic knee surgery
Description: Unilateral prosthetic knee surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral prosthetic knee surgery
Description: Unilateral prosthetic knee surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia
Description: Analgesic management by adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Analgesia
Description: Analgesic management by adductor canal block
Study: NCT05797805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: The first part is a phase 1 single-agent dose escalation, optimization, and expansion study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy.~Tegavivint single agent dosing regimen: Tegavivint will be administered weekly on Days 1, 8, 15, and 22 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In the second part of the study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose escalation followed by a randomized dose optimization.~Tegavivint plus pembrolizumab combination dosing regimen: Tegavivint will be administered weekly on Days 1, 8, and 15 of a 21-day cycle; Pembrolizumab will be administered on Day 1 of a 21- day cycle
Study: NCT06069154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis
Description: Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Local anesthetic peripheral nerve block
Description: Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cryoneurolysis
Description: Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham peripheral nerve block
Description: Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
Study: NCT06572254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Childhood Development Newborn Parenting Education Program
Description: Investigators will be adapting the model used here at the tertiary care of newborn parenting which investogators have developed based on the nurturing care framework and keys to the caregiving framework. Both models have shown reliable evidence of their effectiveness.
Study: NCT05494398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.
Study: NCT05494112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Celastrol
Description: same dose of Celastrol will be given every day for a period of 90-days to all participants.
Study: NCT05415644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets
Description: High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hrx0701 tablets
Description: High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).
Study: NCT05798923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM-001
Description: LAM-001 administered via dry powder inhalation
Study: NCT05165368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraneural Facilitation® Therapy (INF® Therapy)
Description: INF® Therapy plus dietary education with weekly follow-up by a physical therapist. Includes meal preparation ideas and sample menus promoting a gluten-free diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: INF® Therapy
Description: INF® Therapy only (INF® Therapy is a manual therapy technique that consists of three components. The first is the pressurization or facilitation hold which biases circulation more consistently in the nerves, which is thought to pressurize the entire system The secondary hold attempts to stretch the innervated structure, pulling apart the tough dividing membrane and allowing the pressurized blood flow to transport from the outside holding chamber to the endoneurium and push open the closed capillary beds next to the nerve axons. Once capillaries surrounding the nerves are pressurized, the circulation needs to be induced up the neural connective tissue. A separate set of pressure points or holds are performed distal to the secondary holds to ensure the circulation is drawn up the inflamed capillary beds using the Bernoulli principle.)
Study: NCT06213974

Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study: NCT05918055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: 5-10 mg PO daily for 10-14 days based on dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-8602
Description: 5-10 mg PO daily for 10-14 days based on dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inqovi
Description: Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inqovi
Description: Inqovi will be administered via oral route once daily on Days 1-5 of each treatment cycle, according to guidelines outlined in the FDA product label.
Study: NCT06583148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive the smoke-free home program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05502016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Model Diabetes Self-Management Education and Support
Description: Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Model Diabetes Self-Management Education and Support (Wait-list)
Description: Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
Study: NCT06583148

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05084937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeliCAT form
Description: Systematic summary to support transition
Study: NCT05522036

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metvix + Dermaris
Description: Photodynamic Therapy
Study: NCT05404022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored nutrition and physical activity programme
Description: Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required
Study: NCT05861544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: The pomegranate juice that will be used in the experiment is a 100% natural product without conservatives. It will kindly be donated from the company Rodi Hellas SA, Pella, Greece. The product is in line with the quality assurance certificates by the International Organization for Standardization (ISO 22000:2005), Global Gap, Grasp and Kosher.
Study: NCT05341921

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Nostril Breathing
Description: Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate Nostril Breathing
Description: Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bhramari Breathing
Description: Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bhramari Breathing
Description: Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sheetali Breathing
Description: Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sheetali Breathing
Description: Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
Study: NCT05343793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx-Internal Facilitation (NIATx-IF)
Description: Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx-Internal Facilitation (NIATx-IF)
Description: Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
Study: NCT06292273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block with bupivacain Plus dexamethasone
Description: Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus Abdominis Plane Block with bupivacain
Description: plain bupivacaine 0.25%, 25 ml bilaterally
Study: NCT05536947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread product (standard milled)
Description: Bread rolls made from standard milled flour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread Product (micro-milled)
Description: Bread rolls made from micro-milled whole grain flour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread Product (standard aleurone)
Description: Bread rolls made from white flour/standard milled aleurone mix

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread product (micro-milled aleurone)
Description: Bread rolls made from white flour/micro-milled aleurone mix.
Study: NCT05711550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Neurofeedback
Description: Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Neurofeedback
Description: Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Neurofeedback
Description: Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Neurofeedback
Description: The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Neurofeedback
Description: The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Neurofeedback
Description: The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
Study: NCT05014100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib tablet
Description: Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
Study: NCT04702074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine granules
Description: Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Chinese medicine granules placebo
Description: Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules .